JPRN-jRCTs021230062尚未招募1 期
A safety study of total neoadjuvant therapy (TNT) for locally advanced lower rectal cancer
Shinobu Ohnuma0 个研究点目标入组 35 人开始时间: 2024年2月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •1) Biopsy of the primary rectal lesion has been histologically diagnosed as adenocarcinoma.
- •2) The tumor predominantly occupies the upper rectum (Ra), lower rectum (Rb), or anal canal (P)
- •3) The lower border of the tumor lies between the peritoneal inversion and the anal verge
- •4) Tumor depth is cT3-4
- •5) No evidence of distant metastasis
- •6) Tumor is resectable
- •7) Patient is at least 20 years of age at the time of consent
- •8) ECOG performance status (PS) of 0 or 1
- •9) All of the following are met for the most recent laboratory values within 14 days prior to enrollment
- •i) Neutrophil count > 1500/mm3
- •ii) Total bilirubin < 1.5 mg/dl
- •iii) AST < 100U/L
- •iv) ALT < 100U/L
- •v) Creatinine < 1.5mg/dl
- •10) Written consent for participation in this study has been obtained from the patient
排除标准
- •(Exclusions to influence efficacy evaluation)
- •(1)Patients with active multiple cancers
- •(2) Patients with infectious diseases requiring systemic treatment
- •(3)Patients with a fever of 38.0 degrees Celsius or higher at the time of enrollment.
- •(Exclusion to influence safety evaluation)
- •(4)Patients with allergy to 5-FU, capecitabine, or oxaliplatin
- •(5)Women who are pregnant, possibly pregnant, within 28 days postpartum, or breastfeeding
- •(Excluded from the risk/benefit balance)
- •(6) Patients with psychosis or psychiatric symptoms that would make participation in the study difficult
- •(7) Patients with uncontrolled hypertension
- •(8)Patients with unstable angina (angina with onset or worsening within the last 3 weeks) or a history of myocardial infarction within 6 months
- •(9)Patients who are positive for HBs antigen or HCV antibody.
- •(10)HIV antibody-positive patients (pre-enrollment measurement of HIV antibodies is not required, but positive HIV antibodies are considered ineligible).
- •(11)Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema, as diagnosed by CT chest scan, or with one or more of the following complications
- •Translated with www.DeepL.com/Translator (free version)
研究者
相似试验
招募中
3 期
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.JPRN-jRCT1080224903ovartis Pharma. K.K.200
已完成
2 期
Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II studyColon cancerJPRN-UMIN000006742Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group195
招募中
不适用
OUTCOME AND TOXICITY OF TOTAL NEOADJUVANT THERAPY IN RECTAL CANCERC20Malignant neoplasm of rectumDRKS00033000niversitätsklinikum Jena350
已完成
不适用
A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.unresectable colorectal cancerJPRN-UMIN000022535Gunma University45
已完成
不适用
The evaluation of the efficacy and the safety of TSUMURA Tokishakuyakusan Extract Granules for Ethical Use on endometriosis patients with dysmenorrheaEndometriosisJPRN-UMIN000017908Tottori University Faculty of Medicine15
